Clinical Trials Logo

Lung Diseases, Obstructive clinical trials

View clinical trials related to Lung Diseases, Obstructive.

Filter by:

NCT ID: NCT03353064 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease

Telemedicine for Improving Outcome in Inner City Patient Population With Hypercapneic Respiratory Failure

ETOUCH
Start date: October 18, 2017
Phase: N/A
Study type: Interventional

The Hypercapnia Telemedicine Outreach Program (E-TOUCH Study) aims to utilize telemedicine technology, as well as emergency medical services (EMS) home visits to address the problem with poor follow-up and compliance among Einstein's hypercapnic patients. The hypothesis is that reaching out to the subjects' homes will allow more consistent healthcare delivery, increase healthcare efficiency and compliance with therapy, and overall decrease acute decompensated states / hypercapnic respiratory failure, decreasing ED visits and hospitalization.

NCT ID: NCT03345407 Terminated - Clinical trials for Pulmonary Disease, Chronic Obstructive

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Start date: November 28, 2017
Phase: Phase 2
Study type: Interventional

Nemiralisib is being developed as an anti-inflammatory drug for the treatment of inflammatory airways disease. This study is designed to assess the dose response, efficacy, safety, and pharmacokinetics of nemiralisib across a range of doses [up to 750 micrograms (µg)] compared with placebo. The study consists of a Screening Period, a 12-Week Treatment Period and a 12-Week Post-Treatment Follow-Up Period. Approximately 1,250 subjects with an acute moderate or severe exacerbation of COPD requiring standard of care (SoC) therapy will be randomized in this double-blind study. Subjects will be randomized to receive different doses of nemiralisib or placebo via ELLIPTA® inhaler. The total duration of study participation is approximately 6 months (170 days). ELLIPTA is the registered trademark of GlaxoSmithKline (GSK) group of companies.

NCT ID: NCT03337958 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Education With Inhalers in Patients With COPD Exacerbation

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

Chronic obstructive pulmonary disease (COPD) is a public health problem with great morbidity. The main therapeutic strategy is inhalers. The objective of this study is to determine the efficacy of an educational intervention in the use of inhalers in patients with COPD including ventilatory re-education and video recordings of the patients themselves.

NCT ID: NCT03337854 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Analysis With Clusters of QUAntitative Tomodensitometric Vascular, bronchIal and Parenchymal Pulmonary Parameters for COPD Patients

ACQUAVIP
Start date: December 20, 2017
Phase: N/A
Study type: Observational

Chronic obstructive pulmonary disease (COPD) is caused by tobacco consumption. The goal is to characterize on clinical and radiological data, using computed tomography, this illness in order to improve diagnostic and be able to evaluate the prognostic of each patient.

NCT ID: NCT03331302 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy

Start date: September 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Hyper polarized Xenon-129 MRI will be directly compared to a radioactive Xe-133 scintigraphy to detect defects in lung ventilation from airflow limitation. This study is conducted as a pilot study with intention to conduct a larger clinical trial.

NCT ID: NCT03327181 Active, not recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Short Chain Fatty Acid Metabolism in COPD

SCFA
Start date: April 19, 2017
Phase: N/A
Study type: Interventional

The short chain fatty acid (SCFA) metabolism has not been studied in subjects suffering from COPD. The purpose of this study is to compare the SCFA metabolism in COPD patients to healthy matched controls. This protocol is an extension of recent studies about protein digestion and absorption abnormalities in COPD patients. The investigators hypothesize that SCFA production might be lower in COPD patients than in healthy subjects.

NCT ID: NCT03323190 Withdrawn - Clinical trials for Chronic Obstructive Pulmonary Disease

An Educational Intervention to Improve Disease Management Knowledge of Hospitalized Patients With COPD

Start date: August 30, 2016
Phase: N/A
Study type: Interventional

The objective of this study is to determine if inpatient COPD education would result in improved patient knowledge of COPD.

NCT ID: NCT03321279 Completed - Diabetes Clinical Trials

Social Incentives to Increase Mobility

MOVE IT
Start date: January 11, 2018
Phase: N/A
Study type: Interventional

This study aims to assess the effectiveness of a social incentive-based gamification intervention to increase physical activity in the 3 months after hospital discharge.

NCT ID: NCT03313570 Completed - COPD Clinical Trials

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Start date: August 10, 2015
Phase: Phase 3
Study type: Interventional

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT ID: NCT03312322 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Effects of Lumbar Transcutaneous Electrical Nerve Stimulation on Exercise Performance in Patients With Chronic Obstructive Pulmonary Disease

LENS-REHAB
Start date: December 12, 2017
Phase: N/A
Study type: Interventional

Chronic obstructive pulmonary disease is a leading cause of morbidity and mortality worldwide. Pulmonary rehabilitation effectively improves outcomes in patients with chronic respiratory disease. There is a link between training intensity and physiological improvements following pulmonary rehabilitation. However, high intensity training is not sustainable for every patients. Therefore, actual strategies for pulmonary rehabilitation aimed at decreasing dyspnea to improve muscle work. Electrical muscle stimulation is widely used during rehabilitation to promote muscle function recovery. Transcutaneous electrical nerve stimulation was recently used to relief dyspnea and improve pulmonary function in patients with chronic respiratory disease. Moreover, spinal anesthesia with fentanyl has been shown to be effective in improving exercise tolerance in patients with chronic obstructive pulmonary disease (inhibiting group III and IV muscle afferents). As transcutaneous electrical muscle stimulation stimulates the same receptors in the spinal cord dorsal horn as fentanyl, it is hypothesized that it could also improve exercise capacity. Therefore, the aim of this study is to assess wether transcutaneous electrical stimulation (high or low frequency) is effective in improving exercise capacity in patients with severe to very severe chronic obstructive pulmonary disease.